Arcus Biosciences, Inc. (RCUS) earnings
RCUS earnings moved a median of +1.20% by the close. Quarterly and annual RCUS reports and results, each read against the price at its own news timestamp. Back to the RCUS overview →
27 measured RCUS earnings events.
Where these RCUS earnings landedvs 27 measured RCUS earnings reactions
| Middle 50% of RCUS earnings reactions | -3.42% to +3.92% |
|---|---|
| Median reaction (to close) | +1.20% |
| Measured reactions | 27 |
Point-in-time · zero look-ahead
Half of the 27 RCUS earnings events with a measured close landed between -3.42% and +3.92%; 56% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update | Press release | -4.32% | -3.64% | |
| Form 10-Q Arcus Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | -4.32% | -3.64% | |
| Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates | Press release | +0.41% | +2.60% | |
| Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update | Press release | +0.12% | +3.92% | |
| Form 10-Q Arcus Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.12% | +3.92% | |
| Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates | Press release | +0.00% | +6.48% | |
| Form 10-K Arcus Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.06% | -1.76% | |
| Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update | Press release | +0.50% | +1.20% | |
| Form 10-Q Arcus Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.50% | +1.20% | |
| Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update | Press release | +4.81% | -6.92% | |
| Form 10-Q Arcus Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | +4.81% | -6.92% | |
| Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update | Press release | -0.94% | +7.66% | |
| Form 10-Q Arcus Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.94% | +7.66% | |
| Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update | Press release | +0.61% | -1.22% | |
| Form 10-K Arcus Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | -5.48% | -13.19% | |
| Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update | Press release | -0.83% | +2.05% | |
| Form 10-Q Arcus Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.83% | +2.05% | |
| Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update | Press release | -0.51% | +3.77% | |
| Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update | Press release | -0.30% | +4.76% | |
| Form 10-Q Arcus Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | -0.30% | +4.76% | |
| Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update | Press release | -0.07% | +3.13% | |
| Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update | Press release | -5.19% | -4.78% | |
| Form 10-Q Arcus Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | -5.19% | -4.78% | |
| Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update | Press release | +0.11% | -0.39% | |
| Form 10-K Arcus Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.78% | +13.90% | |
| Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update | Press release | +0.00% | -3.20% | |
| Form 10-Q Arcus Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -3.20% |
Keep exploring
More RCUS: analyst actions → · SEC filings → · RCUS overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Penumbra, Inc. (PEN) | 369 | +0.06% | 60% |
| Kura Oncology, Inc. (KURA) | 368 | -0.13% | 49% |
| Ligand Pharmaceuticals Incorporated (LGND) | 367 | +0.06% | 52% |
| Microbot Medical Inc. (MBOT) | 366 | -0.19% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.